Abnormal cannabidiols as agents for lowering intraocular pressure
The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R 1 and R 2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.
1. A compound of formula IV or tautomers thereof
wherein Q is
wherein W is C(R 11 )(R 12 ); a dotted line represents the presence or absence of a double bond; the wavy line represents a direct bond;
wherein Z is C or N;
R is selected from the group consisting of H, halogen and C 1-5 alkyl;
R 1 is selected from the group consisting of H and halogen;
R 2 is independently selected from the group consisting of H, C 1-5 alkyl, halogen, and OC 1-5 alkyl;
R 3 is selected from the group consisting of H, hydroxyl, and C 1-5 alkyl;
R 4 , is selected from the group consisting of H, C 2-5 alkenyl, and C 1-5 alkyl; and R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are independently selected from the group consisting of H, and C 1-5 alkyl.
2. The compound of claim 1 wherein R is selected from the group consisting of hydrogen, methyl, bromo and chloro; R 1 is selected from the group consisting of hydrogen and chloro, R 2 is hydrogen, R 3 is methyl, R 5 R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are hydrogen and R 4 is isopropenyl.
3. The compound of claim 1 wherein said compound is 1-Cyclohexyl-6-methylpiperidine-2,4-dione.
4. The compound of claim 1 wherein said compound is 1-(3,3,5,5-Tetramethylcyclohexyl)piperidine-2,4-dione.
5. A pharmaceutical composition which is an ophthalmic solution comprising a therapeutically effective amount of a compound according to claim 1 .
6. The pharmaceutical composition of claim 5 , wherein the ophthalmic solution comprises at least one ingredient selected from the group of an ophthalmically acceptable preservative, buffer system, antioxidant and chelating agent.
7. A pharmaceutical product, comprising a container adapted to dispense its contents in metered form; and an ophthalmic solution therein, as defined in claim 6 .